NBS Molecular Resources Website

2015 NBS Molecular Training Workshop

Laura Hancock, M.S.

Molecular Quality Improvement Program


Newborn Screening and Molecular Biology Branch,

Division of Laboratory Sciences

NCEH, CDC



State of Molecular Screening in 2015



NBS Molecular Resources Website Resources Available

- Find liquid handling options by viewing detailed summaries of instruments used by other NBS programs
- Research Molecular Assays by reviewing detailed summaries of assays used by other NBS programs
- Access the Molecular Assessment Program (MAP) site visit checklist and request a MAP visit



POLICY

MY CAREER

EDUCATION

ABOUT APHL CONFERENCES

Public Health Labs

Newborn Screening

Preparedness

Lab Matters

Global Health

Awards



Happy 50th Birthday, Newborn Scre

APHL celebrates 50 years of saving babies lives with a PSA on the CBS ju

MEMBER SHIP

PROGRAMS

RESOURCE CENTERS

- Environmental Health
- Food Safety
- Global Health
- Infectious Diseases
- Informatics
- Laboratory Systems And Standards
- Newborn Screening And Genetics
- Public Health Preparedness And Response
- Research

TRAINING AND CONFERENCES

CALIFORNIA SIGNATURE SERIES SEMINAR

Clinical Microbiology Below the Belt!

Ontario, California | February 28, 2013

NATIONAL LABORATORY TRAINING NETWORK

Packaging and Shipping: Division 6.2 Materials

Online Course | Free Registration - Now Open!

View All Training and Register Online >>

View All Conferences and Register Online >>

NEW AT APHI

Times Square. Learn More »



JUST RELEASED

Newborn Screening: Four Facts Policymakers Need to Know



DETECTING AND CONTROLLING INFLUENZA

Public Health Labs on Alert to Find

Flu

Increase your visibility to laboratories in public healt

Learn More »



View All Corporate Members »

www.aphl.org

APHL | Association of Public Health Laboratories

Search...

Q

ABOUT APHL

CONFERENCES

EDUCATION

MEMBERSHIP

MY CAREER

POLICY

PROGRAMS

RESOURCE CENTERS

- Environmental Health
- Food Safety
- Global Health
- Infectious Diseases
- Informatics
- Institutional Research
- Laboratory Systems and Standards
- Newborn Screening and Genetics

Molecular Resources

Assuring Laboratory Quality Newborn Screening Technical assistance and Evaluation Program (NewSTEPs)

 Public Health Preparedness and Response

TEXT SIZE T



Newborn Screening and Genetics



APHL strengthens the role of public health laboratories in genetics testing and newborn screening science and practice.

SAVED TOPICS: Genetics, Newborn Screening



REGISTER NOW

Conferences, Workshops and Webinars



GET ANSWERS TO YOUR QUESTIONS

Resources



NEWSTEPS

Newborn Screening Technical assistance and Evaluation Program (NewSTEPs)



MEET THE NEWBORN SCREENING HEROES

Babies' and Families' Video Stories

CONTACT

JELILI OJODU, MPH

Director of Newborn Screening and Genetics 240.485.2772 jelili.ojodu@aphl.org


¥ SAVE B PRINT M SEND

Share This

ITEMS FOR PURCHASE

Buy Books, Brochures

Buy Shirts



ABOUT APHL CONFERENCES **EDUCATION** MEMBERSHIP MY CAREER POLICY **PROGRAMS** RESOURCE CENTERS

- ► Environmental Health
- Food Safety
- Global Health
- Infectious Diseases
- Informatics
- Institutional Research
- Laboratory Systems and Standards
- Newborn Screening and Genetics

Molecular Resources Assuring Laboratory Quality Newborn Screening Technical assistance and Evaluation Program (NewSTEPs)

 Public Health Preparedness and Response



LEARN MORE > >

Newborn Screening and Genetics

Liquid Handling Options

SAVED TOPICS: Newborn Screening

When exploring automation commonly used in molecular newborn screening, there are two levels of automation: highly automated, in which the technician has little to no intervention until the method set up is complete; and semi-automated, which is a combination between the manual and the automated levels. In a semi-automated method, the technician will often use instruments on the front end of a method to assist adding reagents. All other steps are completed manually.

Semi-Automated

- Used when processing a small (<500) to medium (>500) daily number of specimens
- Used for adding reagents directly into plate wells
- Does not work when mixing is required
- Instrument used to assist technician with addition of reagents, however other instruments are often used to complete the method
- No specialty positions on deck available (instrument cannot include barcode readers, heated peltier, plate shakers or plate hotels)
- Cannot be used for selective choosing of specimens (aspirating or dispensing to one specimen at a time, i.e. "cherry picking")
- Technician must be present while instrument(s) is running
- Small footprint
- Cheaper than highly-automated instruments

Highly-Automated

- · Used when processing a medium to large daily number of specimens
- Used for adding reagents directly into plate, washing specimens, mixing specimens, and removing buffers from specimens
- . Level of automation is flexible. Methods can be written to any level of user assistance; from zero user assistance needed, technician can walk away upon starting the method; or partial assistance with one or more step(s) completed with technician assistance
- Many specialty positions available. Common positions found in NBS labs include: barcode readers, heated peltier, plate shakers and plate/tip hotels
- Medium to large footprint
- More expensive than semi-automated instruments

SAVE PRINT SEND









CONTACT

GUISOU PIÑEYRO, MS, MPH

Senior Specialist, Newborn Screening & Genetics 240.485.2736(2) guisou.pineyro@aphl.org

LAURA HANCOCK, MS

Research Biologist, Newborn Screening & Molecular Biology Branch - CDC Ifn2@cdc.gov

Title

Robotic one 8 channel liquid handler

Robotic 96-channel Liquid Handler

Robotic one 8-channel and 96-channel Liquid Handler

Photo



Picture Courtesy of the Michigan Department of Community Health



Picture Courtesy of the Georgia Department of Public Health



Picture Courtesy of New York State Department of Health - Wadsworth Center

Mode Of Operation

Aspirates & dispenses or multi-dispenses between 1 and 8 channels at a time.

Simultaneously aspirates & dispenses and multi-dispenses up to 96-channels at a time.

Instrument has two dispensing mechanisms. One that aspirates & dispenses between 1- and 8-channels at a time. The other arm simultaneously aspirates & dispenses and multi-dispenses up to 96-channels at a time.

DNA Extraction

Used when extracting one plate at a time.

Used when extracting 1 to 4 plates at a time. Used when method includes 1 or more

Used when extracting 1 to 8 plates at a time. Used with 96 head arm when method

Used when method includes 1 wash of DBS punches. Please note that this can be used when multiple washes are needed. However many NBS labs currently use a vacuum apparatus to remove wash buffer and leave punches in well, therefore increasing the amount of time a laboratorian must interact with the method. Please note that vacuum is a separate instrument, and is not attached to liquid handler.

washes of DBS punches, NBS labs currently have methods that effectively remove the wash buffer and leave the DBS that effectively remove the wash buffer punches in the wells.

and leave the DBS punches in the wells.

includes 1 or more washes of DBS

Used for addition of elution solution.

Used with 1- to 8-channel head for addition of elution solution.

punches. NBS labs currently have methods

Used for addition of elution solution.

PCR Set-Up Used for addition of PCR master mix.

Use for addition of DNA to PCR plate.

Used for addition of PCR master mix on instrument with the selective tip head.

Used for addition of PCR master mix on instruments that only have the ability to simultaneously aspirate 96-wells at a time, to PCR plate. however this is often an expensive reagent and a large excess volume must be added to the instrument to fill the 96-well reservoirs.

Used with 1 to 8 head for addition of PCR master mix on instrument with the selective tip head.

Used with 96 head arm for addition of DNA

Health

Newborn Screening and Genetics

ases

Molecular Resources

SAVED TOPICS: No Save Topics for this page.

search

tems and

ening and

ces

ory Quality ng Technical valuation EPs)

and

Т

AUTOMATION METHODS

Find the Liquid Handling Instrument that Fits Your Needs:

Liquid Handling Options

Automation Methods

Questions to Ask When Purchasing a Liquid Handler

MOLECULAR METHODS

View State NBS Laboratory Assays

QUALITY IMPROVEMENT

Molecular Assessment Program (MAP)

Some content is restricted access; if you have trouble accessing content but believe you should have access, please reach out to your newborn screening program staff contact of choice.

CONTACT

GUISOU PIÑEYRO

Senior Specialist, & Genetics 240.485.2736 guisou.pineyro@a

Your Lab's Best Friend!

Newborn Screening and Genetics

Molecular Resources

SAVED TOPICS: No Save Topics for this page.

ınd

nical

AUTOMATION METHODS

Find the Liquid Handling Instrument that Fits Your Needs:

Liquid Handling Options

Automation Methods

Newborn screening programs across the country have implemented automation for molecular assays into their screening protocols. Select a method below to view automation techniques used in US laboratories or to upload your own.

- · DNA Extraction Method
- PCR Set-Up Method
- · On-Card Assay Method

Questions to Ask When Purchasing a Liquid Handler

MOLECULAR METHODS

View State NBS Laboratory Assays

CONTACT

GUISOU PIÑEY

Senior Special & Genetics 240.485.2736(guisou.pineyro

b's end! Safety

al Health

tious Diseases

matics

utional Research

ratory Systems and dards

oorn Screening and tics

ular Resources

ing Laboratory Quality orn Screening Technical ance and Evaluation am (NewSTEPs)

c Health aredness and onse





Molecular Resources

SAVED TOPICS: No Save Topics for this page.



AUTOMATION METHODS

Find the Liquid Handling Instrument that Fits Your Needs:

Liquid Handling Options

Automation Methods

Newborn screening programs across the country have implemented automation for molecular assays into their screening protocols. Select a method below to view automation techniques used in US laboratories or to upload your own.

DNA Extraction Method

Stato	Contact	# Samples (Busiest Day)	Dispensing Instrument
Minnesota	Berta Wax an	350	Non-robotic 8 channel reagent dispenser
Massachusetts	Jacalyn Thompson	1100	Manual
Michigan	Heather Wood	1200	Robotic 1-8 channel liquid handler

Add New DNA Extraction Method

- · PCR Set-Up Method
- On-Card Assay Method

Questions to Ask When Purchasing a Liquid Handler

MOLECULAR METHODS

CONTACT

GUISOU PIÑEYRO, MS, MPH

Senior Specialist, Newborn Scree & Genetics 240.485.2736 guisou.pineyro@aphl.org

Complete the form below to submit your response For drop down choices, select existing option or type in your answer.


State:	Minnesota		
Contact:	Berta Warman	Alt Contact:	Carrie Wolf
Contact Email:	berta.warman@state.mn.us	Alt Email:	carrie.wolf@state.mn.us
Contact Phone:	651.201.4836	Alt Phone:	651.201.5458
Number of Samples on Busiest Day:	350		
Number of Samples per Year:	70,000		
Dispensing Instrument Used:	Non-robotic 8 channel reagent	dispenser	<u> </u>
Instrument 1 Model (Manufacturer):	Viafill (Integra)		V
Aspirating Instrument Used:	VP 177A-1 aspiration manifold	(V7P Scientific, INC	c) 🔽
Instrument 2 Model (Manufacturer):	N/A		V
Type of DNA Extraction:			\overline{v}
Assay:	CF and SCID		\overline{v}

Manage	CI	ose		
How Man are Neede Instrumer	ed to Run	this	1	
Plate Use	d for Extr	raction	96 well, unskirted PCR plate, v bottom	
Size of Pu	nch Extra	acted:	3.2 mm	
Number o		s for	3	
If Washes What Tem		-	N/A	
Extra Volu Added to Assure Ac Pipetting:	Reservoi curate		N/A	
Describe 1	Wash 1:		1. 150 μ l of Purificartion solution 1 (Qiagen) is added to each well containing a DBS using the Viafill. 2. Plate is	^
Describe applicabl		(if	1. 150µl of Purification solution 1 is added to each well containing a DBS using the Viafill. 2. Plate is shake for 15 min. on the Vortemp 56 shaking-incubator at room	^
Describe applicabl		(if	1. 150µl of Elution solution 2 (Qiagen) is added to each well containing a DBS using the Viafill. 2. Plate is shake for 15 min. on the Vortemp 56 shaking-incubator at room	^

Describe Wash 4 (if applicable):	N/A
Average Number of Spots Lost During Wash Removal:	0.01%
Detail How Liquid is Removed During Wash to Leave Spot:	with an 96 well aspiration manifold
Elution Volume:	25ul
Describe Elution:	Elution solution 2 (Qiagen) is added, plate is sealed with thermal sealing foil and placed in the Vortemp 56 shaking-incubator @ 900rpm for 30 minutes at 99.5oC.
Level of Automation:	Semi-automated 🔻
Describe User Intervention Step(s) (if applicable):	Apply and remove adhesive film. Transfer plates from one instrument to the other. Press "start" on each instrument.
Smallest Volume Pipetted:	25 ul
Largest Volume Pipetted:	150 ul
List Speciality Positions Used:	N/A
Number of Plates Extracted at Same Time:	2-5

-	
Number of Plates Extracted in 1 Day:	
Is Sample Tracking Required?:	No
Number of Tips Used per Sample:	Non
Are Tips Re-used?:	N/A
Describe How Tips are Used? (One tip per sample, multiple tips per sample, tips used for multiple samples):	N/A
Are Speciality Tips Used?:	No
Time it Takes to Complete Method:	90 minutes (60 minutes in liquid handler, aspirator and RT incubation and 30 mi
How Many Positions on the Deck are Used During Method:	N/A
Important Method Logistics/Hints:	N/A

Important Method Logistics/Hints:	N/A
Describe Other Instruments Used:	Shaker incubator (Vortemp 56)
List Other Methods (Molecular and Non- molecular) that Use this Instrument:	N/A
List of Labware that is Commonly Used with this Method:	Viafill: tubing cassettes (one per solution); Aspirator Manifold: vacuum pump, vacuum trap bottles, tubing
Limitations of Instrument for this Method:	



Newborn Screening and Genetics

Molecular Resources

SAVED TOPICS: No Save Topics for this page.

n

and

ind

AUTOMATION METHODS

Find the Liquid Handling Instrument that Fits Your Needs:

Liquid Handling Options

Automation wethods

Questions to Ask When Purchasing a Liquid Handler

Instrument Hardware

Instrument Software

Instrument Maintenance

Instrument Support

MOLECULAR METHODS

View State NBS Laboratory Assays

CONTACT

GUISOU PI

Senior Spe & Genetics 240.485.27 guisou.pine

Questions to Ask When Purchasing a Liquid Handler

Instrument Hardware


- 1. How much space will this instrument take up? Will existing benches need to be modified (widened, pulled away from the wall, extended)?
- 2. What types of specialty additions can be incorporated?
- 1. Plate shaker
- 2. Barcode reader
- Heating unit
- 3. How many plates/tips can I fit on the deck?
- 4. Can the instrument track samples?
- 5. Is the labware (plates, reservoirs, tips) I plan to use compatible? If not, are there adaptors that can be used?
- 6. What is the cost of the recommended labware? Are there other options for needed labware (other brands) or does it have to be from the same company as the instrument?
- 7. Can low reagent volumes be accurately pipetted? What are the accuracy and precision rates?
- 8. What is the dead volume when pipetting my lowest volume needed from my desired reservoir? Are there other reservoirs available that would decrease my dead volume that would also work for my needs?
- 9. Approximately how long does it take to dispense reagent to a 384 well plate? Into a 96 well plate? From different sources (reservoirs, plates, tubes)
- 10. Can the instrument be used for non-molecular cross purposes?
- 11. Can the instrument be connected to the intranet?
- 12. Do I have a mechanism to purchase this instrument?
- 13. Do I have a mechanism to purchase consumables (tips, plates, reservoirs)?
- 14. Where can I see this instrument in action with a method similar to what I have planned?
- 15. Can I demo the instrument?
- 16. Does our specimen throughput or backup requirements necessitate instrument redundancy (purchase of more than one of the same instrument)?

Instrument Software

- 1. How much control does the user have over the labware descriptions, including plates and tips? (Example - if you need the tip to enter a plate at the side of a well, instead of the middle - can the end user adjust this?) Can the user define their own labware specifications or is that done by the manufacturer?
- 2. What level of programing is required?
- 3. Is the software user-friendly?
- 4. Do we have a person currently in our lab who can manage/maintain the more technical

Instrument Maintenance

- 1. What is covered by the warranty at time of purchase and what options there are when warranty need to be renewed?
- 2. Is this instrument maintenance covered under the contract agreement with my lab?
- 3. Recommendations on how often the instrument has to be shut down (daily, over the weekend,
- 4. What is the required instrument maintenance (daily, weekly, monthly, annually)?



Your Lab Training

artner

- ▶ Global Health
- ► Infectious Diseases
- Informatics
- ► Institutional Research
- Laboratory Systems and Standards
- Newborn Screening and Genetics

Molecular Resources
Assuring Laboratory Quality
Newborn Screening Technical
assistance and Evaluation
Program (NewSTEPs)

Public Health
 Preparedness and
 Response

TEXT SIZE T



State NBS Molecular Assays

SAVED TOPICS: No Save Topics for this page.

Newborn screening programs around the country are in various stages of implementing molecular assays into their screening protocols. Select a disorder to learn about the different molecular methods currently in use in a NBS laboratory.

Please select disorder of interest:

Cystic Fibrosis

STATE	CONTACT PERSON	LABORATORY ASSAY	TIER
Iowa	Mike Ramirez	Hologic InPlex	Second
California	George Helmer	Luminex xMAP	Second
California	George Helmer	DNA Sequencing	Second
Michigan	Kelly TenEyck, M.S.	Hologic InPlex	Second
Minnesota	Amy Hietala	Luminex xMAP	Second
Massachusetts	Anne Mar Comeau, PhD	Luminex xMAP	Second
New York	Dr. Michele Caggana	Hologic InPlex	Second
		-	
New York	Dr. Michele Caggana	Polyacrylamide Gel Electrophoresis	Second
New York Texas	Dr. Michele Caggana Rachel Lee	Polyacrylamide Gel Electrophoresis Hologic InPlex	Second Second
Texas	Rachel Lee	Hologic InPlex	Second
Texas Washington	Rachel Lee Tim Davis	Hologic InPlex Fluorescent Probe Mutation Detection (i.e. TaqMan)	Second Second

- Galactosemia
- Hemoglobinopathies

Krobbo

Molecular Assay Description Form

State:	Massachusetts		
Program Website:	http://www.umassmed.edu/nbs/index.aspx		
Contact Person:	Anne Marie Comeau, PhD	Alt Contact:	jacalyn.thompson@umassmed.edu
Contact Email:	anne.comeau@umassmed.edu	Alt Email:	jacalyn.thompson@umassmed.edu
Contact Phone:	617-983-6300	Alt Phone:	617-983-6300
Condition:	Cystic Fibrosis		
Laboratory Assay:	Luminex xMAP		
Tier:	Second		
Please indicate the method of DNA extraction used in your laboratory:	Qiagen Generation method using in-house prepared wash solution as a substitute for Solution 1, and Solution :		

Extraction Duration (hrs):	1.25	Assay Duration Excluding Extraction (hrs):	5-6 hrs. Duration consists of 4 sets of	of
Mutations or Targets Screened:	Exon3: G85E, 394delTT; Exon4: Y122X, R117H; Intron4: 621+1G>T*; Intron5: 711+1G>T*; Exon7: R347H, R347P*, R334W*, 1078delT*; Exon9:A455E*,5/7/9T; Exon10: deltaI507*,deltaF508*,V520F,F508C,I507V,I506V; Intron 10: 1717-1G>A*; Exon11: A559T, G542X*,G551D*, R553X*, R560T*, S549N, S549R (T>G); Exon12: 1898+1G>A*, Intron12: 1898+5G>T; Exon13: 2307insA, 2183AA>G, 2184delA*; Intron14b: 2789+5G>A*; Intron16: 3120+1G>A*; Exon17b: M1101K, Y1092X (C>A), Y1092X (C>G); Exon19: R1162X*, S1255X (19), 3659delC*; Intron19: 3849+10kbC>T*; Exon20: S1255X (20), 3876delA, 3905insT, W1282X*; Exon21: N1303K*. * indicates that mutation is on ACMG carrier screening panel.			
Assay Description:	regulator (CFTR) gene simultaneously in variants or wild-type sequence. The xTa Polymerase Chain Reaction (PCR) and n	n order to detect and identif g® Cystic Fibrosis 39 v2 ac nultiplex Allele Specific Prii	c Fibrosis transmembrane conductance fy each as containing specific mutations, complishes this objective using multiples mer Extension (ASPE) with Luminex sorting system on the Luminex® analyzer	x
Assay Limitations:		a. Other mutations can be a dependently. 2. the assay is I limitations related to suc	added, but only through a "laboratory	^
	this flexibility. Specifically, all mutatio of the test results. Version 2 appears to		tested and software drives the reporting on 1 per FDA requirement (under	~

Instruments Used for this Assay	Assay Platform/Instrumentation and Manufacturer:
Assay	Luminex 39+4 assay/Luminex 100/200 Reader System
Instruments Used for this	Liquid Handling Robotics Instrumentation and Manufacturer:
Assay - Liquid Handling	Biomek 3000 for transfer of DNA eluate from 96-well plate to PCR tubes (optional)
Robotics Instruments:	
Population Frequency for	The frequency of cystic fibrosis (excluding CRMS and CRD) in the Massachusetts population is about 1 in 380
Disorder Within Your State:	
Important Assay	The Luminex TDAS software included in the kit is excellent for quality control monitoring. This is the same
Logistics /Hints Not	platform that we use for Laboratory-Developed tests for GALT and MCADD.
Described Above (i.e. If	
multiple assays are used	
for this disorder, describe	
how each is used)	

Molecular Resources
Assuring Laboratory Quality
Newborn Screening Technical
assistance and Evaluation
Program (NewSTEPs)

 Public Health Preparedness and Response

TEXT SIZE T T T



Please select disorder of interest:

- Cystic Fibrosis
- Galactosemia
- Hemoglobinopathies
- Krabbe
- · Medium Chain Acyl CoA Dehydrogenase (MCAD)
- Maple Syrup Urine Disease (MSUD)
- Severe Combined Immunodeficiency Disorder (SCID)

Enter Your Assay

Thank you for assisting us to create an accurate summary of all NBS molecular assays currently in use. Please fill out a form for each assay performed by your laboratory. For assistance in completing the form, please contact Laura Hancock, Research Scientist, Newborn Screening and Molecular Biology Branch, CDC at Ifn2@cdc.gov.

Senior Specialist, Newborn Screening & Genetics 240.485.2736 guisou.pineyro@aphl.org

LAURA HANCOCK, MS

Research Biologist, Newborn Screening & Molecular Biology Branch - CDC Ifn2@odc.gov

- ► Environmental Health
- ▶ Food Safety
- Global Health
- ► Infectious Diseases
- Informatics
- ► Institutional Research
- ► Laboratory Systems and Standards
- ▼ Newborn Screening and Genetics

Molecular Resources Assuring Laboratory Quality Newborn Screening Technical assistance and Evaluation Program (NewSTEPs)

Public Health Preparedness and Response

TEXT SIZE T





Newborn Screening and Genetics

State NBS Molecular Assays

SAVED TOPICS: No Save Topics for this page.

Newborn screening programs around the country are in various stages of implementing molecular assays into their screening protocols. Select a disorder to learn about the different molecular methods currently in use in a NBS laboratory.

Please select disorder of interest:

- Cystic Fibrosis
- Galactosemia
- · Hemoglobinopathies
- Krabbe
- Medium Chain Acyl CoA Dehydrogenase (MCAD)
- Maple Syrup Urine Disease (MSUD)
- Severe Combined Immunodeficiency Disorder (SCID)

STATE	CONTACT PERSON	LABORATORY ASSAY	TIER
California	George Helmer	Real Time qPCR	First
Michigan	Heather D Wood, M.S.	Real Time qPCR	First
Massachusetts	Anne Marie Comeau, PhD	Real Time qPCR	First
New York	chele Caggana	Real Time qPCR	First
Texas	Rachel Lee	Real Time qPCR	First
Wisconsin	Mei Baker	Real Time qPCR	First
Colorado	Mark Dymerski	Real Time qPCR	First
Minnesota	Amy Hietala	Real Time qPCR	First
Washington	Tim Davis	Real Time qPCR	First

Enter Your Assay

Thank you for assisting us to create an accurate summary of all NBS molecular assays currently in use. Please fill out a form for each assay performed by your laboratory. For assistance in completing the form, please contact Laura Hancock, Research Scientist, Newborn Screening and Molecular Biology Branch, CDC at Ifn2@cdc.gov.

¥ SAVE ♣ PRINT M SEND







CONTACT

GUISOU PIÑEYRO, MS, MPH

Senior Specialist, Newborn Screening & Genetics 240.485.2738(2) guisou.pineyro@aphl.org

LAURA HANCOCK, MS

Research Biologist, Newborn Screening & Molecular Biology Branch - CDC lfn2@cdc.gov

Molecular Assay Description Form

State:	New York		
Program Website:	http://www.wadsworth.org/newborn/index.html		
Contact Person:	Dr. Michele Caggana	Alt Contact:	Dr. Carlos Saavedra or Jason Isabelle
Contact Email:	mxc08@health.state.ny.us	Alt Email:	cas28@health.state.ny.us or jti02@he
Contact Phone:	518-473-3854	Alt Phone:	518-486-1641 or 518-474-3853
Condition:	SCID		
Laboratory Assay:	Real Time qPCR		
Tier:	First		
Please indicate the method of DNA extraction used in your laboratory:	In house wash/alkaline lysis/boil method (automated)		


Extraction Duration (hrs):	~ 2.5 hrs / 384 samples	Assay Duration Excluding Extraction (hrs):	48 hrs (including retests)
Mutations or Targets Screened:	TREC and RNaseP target screened for in	every newborn.	
Assay Description:	Immune function and T-cell counts are difficult to illicit directly from a dried blood spot. In this case, a substitute marker is used to make this determination. During normal T-cell development in the thymus, a short section of DNA is excised from the T-cell receptor gene. The ends of this linear sequence are ligated together to form a circular DNA episome. This circular piece of DNA is deemed a T-cell receptor excision circle or TREC. A lack or very low number of these TRECs is indicative of a severe T-cell lymphopenia such as that seen in SCID. TREC quantities from a dried blood spot are measured by a quantitative real-time PCR assay that utilizes TaqMan® Chemistry. Specimens with low TREC values are repunched and retested in		
Assay Limitations:	Deletions/mutations in primer or probe sequence would limit assay efficiency.		
Instruments Used for this Assay	Assay Platform/Instrumentation and Ma		

Instruments Used for this	Liquid Handling Robotics Instrumentation and Manufacturer:
Assay - Liquid Handling	Beckman Biomek NXp / INHECO Shaking peltier devices / Thermo Scientific Cytomat Hotel.
Robotics Instruments:	
Population Frequency for	1:44,000
Disorder Within Your State:	
Important Assay	RNaseP and TREC are multiplexed. Due to liquid handler/peltier unit limitations, a modified version of the DNA extraction method was adapted. Separate rooms house preparation of assay solutions, DNA extractions,
Logistics /Hints Not	and reaction runs.
Described Above (i.e. If multiple assays are used	
for this disorder, describe	
how each is used)	


in completing the form, please contact Laura Hancock, Research Scientist, Newborn Screening

and Molecular Biology Branch, CDC at Ifn2@cdc.gov.





Molecular Assay Description Form State: Program Website: Contact Person: Alt Contact: Contact Email: Alt Email: Contact Phone: Alt Phone: <u>~</u> Condition: <u>~</u> Laboratory Assay: ~ Tier: <u>~</u> Please indicate the method of DNA extraction used in your laboratory: Extraction Duration (hrs): Assay Duration Excluding Extraction (hrs): Mutations or Targets Screened: Assay Description: Assay Limitations:



- Environmental Health
- Food Safety
- Global Health
- Infectious Diseases
- Informatics
- ► Institutional Research
- Laboratory Systems and Standards
- Newborn Screening and Genetics

Molecular Resources Assuring Laboratory Quality Newborn Screening Technical assistance and Evaluation Program (NewSTEPs)

 Public Health Preparedness and Response

TEXT SIZE



Newborn Screening and Genetics

Molecular Assessment Program

Improve the quality of your state's Newborn Screening molecular program with a CDC/APHL Molecular Assessment Program (MAP) visit.

SAVED TOPICS: Laboratory Systems and Standards, Newborn Screening, Quality Systems

The CDC's Newborn Screening and Molecular Biology Branch, in cooperation with APHL, offers onsite visits designed to assess the quality of a state newborn screening molecular program. The MAP visits are tailored to the specific needs of the newborn screening program with guidance in evaluating ongoing or soon to be implemented molecular testing procedures. The MAP team of CDC and state public health laboratory scientists work with laboratory personnel to assess of all molecular testing procedures.

Read MAP Testimonials

Get Started

Review MAP Checklist

Review MAP Visit Timeline

Request a MAP Visit

After the MAP visit, the laboratory director receives a summary report and any resources related to specific molecular testing issues that were discussed during the visit. Findings from MAP assessments inform the CDC's Newborn Screening and Molecular Biology Branch's efforts to support newborn screening laboratories.

Follow-Up

Rate your MAP Visit

📑 📘 🧲 Share Th

¥ SAVE ♣ PRINT ☑ SEND

CONTACT

RUHIYYIH DEGEBERG, MPH

Specialist, Newborn Screening and Genetics 240.485.2718 .

ruhiyyih.degeberg@aphl.org

CHRISTOPHER GREENE, PHD

Research Scientist CDC-NSMBB arg0@cdc.gov

RELATED CONTENT

CDC - Newborn Screening Quality Assurance Program molecular testing procedures.

240.485.2718 .

Research Scientist

RELATED CONTENT

CDC-NSMBB

arg0@cdc.gov

ruhiyyih.degeberg@aphl.org

CHRISTOPHER GREENE, PHD

CDC - Newborn Screening

Quality Assurance Program

Read MAP Testimonials



Public Health

Response

Preparedness and

Your Lab Training

LEARN MORE > >

Partner

Your Lab's

Best Friend!

Request a MAP Visit

After the MAP visit, the laboratory director receives a summary report and any resources related to specific molecular testing issues that were discussed during the visit. Findings from MAP assessments inform the CDC's Newborn Screening and Molecular Biology Branch's efforts to support newborn screening laboratories.

Follow-Up Rate your MAP Visit

The Molecular Assessment Program (MAP): Evaluation of Newborn Screening Molecular Testing

Newborn screening (NBS) is the process of testing infants for serious developmental, metabolic, and genetic disorders. The Health and Human Services (HHS) Secretary's Advisory Committee on Heritable Disorders in Newborns and Children (SACHDNC) lists 31 core disorders that are recommended to be included in every NBS program in the United States. These core conditions share criteria including that they are prevalent in the U.S. population; can be screened for using a simple, robust test; and a treatment or intervention exists if the disorder is detected early. The majority of screening for these disorders is through a biochemical test. The recommended inclusion of cystic fibrosis (CF) to the core panel of disorders in the mid-2000s resulted in the first wide-spread use of a molecular test in NBS to increase the sensitivity and specificity of biochemical screening results. In addition to CF, several programs adopted second-tier molecular tests for disorders including galactosemia, MCAD, PKU, and CAH. In 2010, the SACHDNC added Severe Combined Immunodeficiency (SCID) to the core screening panel. This disorder signified the first time a molecular assay was used as a primary screening test. The inclusion of SCID will require the expansion of molecular testing activities in NBS programs. Despite the increased use of molecular testing, there are still several public health programs that have yet to introduce molecular testing into their NBS programs.

As NBS laboratories introduce molecular assays into their routine testing, it is imperative that the specific concerns related to molecular testing are addressed to ensure the quality of test performance and laboratory practice. Molecular testing requires specific guidelines that are not covered by CLIA. In response to this, the Newborn Screening Molecular Subcommittee developed a pilot initiative, the Molecular Assessment Program (MAP). MAP will involve the public health laboratory personnel working together with the NSMBB molecular quality improvement program to provide quality management guidance for molecular testing in NBS

3A: Unidirectional Workflow
3A.1: Does the laboratory have clearly defined pre-PCR and post-PCR laboratory spaces? N/A YES NO
Comments:
3A.2: Are pre-PCR and post-PCR laboratory spaces physically separated in different rooms? N/A YES NO
Comments:
3A.3: If pre-PCR and post-PCR areas are in the same room, does the laboratory utilize enclosed
dead-air boxes to minimize contamination? N/A YES NO
Comments:

Response

TEXT SIZE



Get Started

Review MAP Chacklist

Review MAP Visit Timeline

Request a MAP Visit

After the MAP visit, the laboratory director receives a summary report and any resources related to specific molecular testing issues that were discussed during the visit. Findings from MAP assessments inform the CDC's Newborn Screening and Molecular Biology Branch's efforts to support newborn screening laboratories.

CHRISTOPHER GREENE, PHD

CDC - Newborn Screening

Quality Assurance Program

Research Scientist

RELATED CONTENT

CDC-NSMBB

arg0@cdc.gov

Follow-Up

Rate your MAP Visit

MY CAREER

Environmental Health

ABOUT APHL

CONFERENCES

- Food Safety
- Global Health
- Infectious Diseases
- Informatics
- ► Institutional Research
- Laboratory Systems and Standards
- Newborn Screening and Genetics

Molecular Resources Assuring Laboratory Quality Newborn Screening Technical assistance and Evaluation Program (NewSTEPs)

 Public Health Preparedness and Response

TEXT SIZE T



Newborn Screening and Genetics

MEMBERSHIP

EDUCATION

Molecular Assessment Program

Improve the quality of your state's Newborn Screening molecular program with a CDC/APHL Molecular Assessment Program (MAP) visit.

POLICY

PROGRAMS

SAVED TOPICS: Laboratory Systems and Standards, Newborn Screening, Quality Systems

The CDC's Newborn Screening and Molecular Biology Branch, in cooperation with APHL, offers onsite visits designed to assess the quality of a state newborn screening molecular program. The MAP visits are tailored to the specific needs of the newborn screening program with guidance in evaluating ongoing or soon to be implemented molecular testing procedures. The MAP team of CDC and state public health laboratory scientists work with laboratory personnel to assess of all molecular testing procedures.

Read MAP Testimonials

Get Started

Review MAP Checklist

Review MAP Visit Timeline

Request a MAP Visit

After the MAP visit, the laboratory director receives a summary report and any resources related to specific molecular testing issues that were discussed during the visit. Findings from MAP assessments inform the CDC's Newborn Screening and Molecular Biology Branch's efforts to support newborn screening laboratories.

Follow-Up

Rate your MAP Visit

CONTACT

RESOURCE CENTERS

RUHIYYIH DEGEBERG, MPH

Specialist, Newborn Screening and Genetics 240.485.2718 .

¥ SAVE ♣ PRINT ☑ SEND

📑 📘 🧲 Share Th

Q

ruhiyyih.degeberg@aphl.org

CHRISTOPHER GREENE, PHD

Research Scientist CDC-NSMBB arg0@cdc.gov

RELATED CONTENT

CDC - Newborn Screening Quality Assurance Program





Commit

Clipboard

Representative Name:	Laura Hancock
Phone Number:	770-488-4617
Email Address:	Ifn2@cdc.gov
NBS Laboratory Name:	Centers for Disease Control and Prevention
NBS Laboratory Director:	Suzanne Cordovado
City:	Atlanta
State:	Georgia
Molecular Assays in Use by NBS Laboratory:	Cystic Fibrosis
Molecular Assays Expected in Next Six Months:	SCID
Reason for Visit Request (check all that apply)	□ Preparation for CAP ☑ Preparation for CLIA □ New Molecular Lab ☑ Expanding to Include New Assay □ Performance Evaluation ☑ Molecular Lab Design ☑ If your reason is not in this list please let us know in the blank box provided.

APHL | Association of Public Health Laboratories

Search...

Q

ABOUT APHL

CONFERENCES

EDUCATION

MEMBERSHIP

MY CAREER

POLICY

PROGRAMS

RESOURCE CENTERS

- Environmental Health
- Food Safety
- Global Health
- Infectious Diseases
- Informatics
- Institutional Research
- Laboratory Systems and Standards
- Newborn Screening and Genetics

Molecular Resources

Assuring Laboratory Quality Newborn Screening Technical assistance and Evaluation Program (NewSTEPs)

 Public Health Preparedness and Response

TEXT SIZE T



Newborn Screening and Genetics



APHL strengthens the role of public health laboratories in genetics testing and newborn screening science and practice.

SAVED TOPICS: Genetics, Newborn Screening



REGISTER NOW

Conferences, Workshops and Webinars



GET ANSWERS TO YOUR QUESTIONS

Resources



NEWSTEPS

Newborn Screening Technical assistance and Evaluation Program (NewSTEPs)



MEET THE NEWBORN SCREENING HEROES

Babies' and Families' Video Stories

CONTACT

JELILI OJODU, MPH

Director of Newborn Screening and Genetics 240.485.2772

¥ SAVE B PRINT M SEND

😭 📔 🤇 ShareThis

jelili.ojodu@aphl.org

ITEMS FOR PURCHASE

Buy Books, Brochures

Buy Shirts

- roou salety
- Global Health
- ► Infectious Diseases
- Informatics
- ► Institutional Research
- ► Laboratory Systems and Standards
- ▼ Newborn Screening and Genetics

Molecular Resources Assuring Laboratory Quality Newborn Screening Technical assistance and Evaluation Program (NewSTEPs)

Public Health Preparedness and Response

TEXT SIZE T



Conferences, Workshops and Webinars

APHL regularly hosts small conferences, workshops and trainings concerning newborn screening.

SAVED TOPICS: Conferences, Genetics, Newborn Screening, Webcasts





Tandem Mass Spectrometry Laboratory Workshop

Applications are now open for the upcoming course, "Newborn Screening by Tandem Mass Spectrometry (MS/MS): A Hands-On Course in Understanding Laboratory Issues and Interpreting Test Results," The course is a five-day intensive workshop and is co-sponsored by the Association of Public Health Laboratories (APHL) and the Centers for Disease Control and Prevention (CDC). The course will be held at the Newborn Screening and Molecular Biology Branch Laboratories at CDC in Atlanta, GA on April 20-24, 2015. The course will feature MS/MS hands-on exercises designed to enhance understanding of the didactic portions of the workshop. The exercises will cover routine MS/MS newborn screening tests as well as second tier testing using MS/MS methods applicable to the modern newborn screening system.

Apply today. Applicants must be logged into their APHL accounts in order to apply. Accounts are easy to create and are free of charge. Don't have an account? Click here. Have an account but forgot your password? Click here. Applications will be open until close of business on Friday. February 20, 2015.

Free CEs for Laboratory and Health Professionals Involved in Biochemical Genetic Testing

Laboratory professionals working in biochemical genetic testing or newborn screening laboratories who are looking for CE opportunities are encouraged to read the 2012 MMWR Recommendation and Reports: Good Laboratory Practices for Biochemical Genetic Testing and Newborn Screening for Inherited Metabolic Disorders and take a post-test to document knowledge gained and earn CEs. The document can be used to prepare for an upcoming accreditation or laboratory certification inspection, strengthen a laboratory's quality improvement program, and assist in developing a competency testing plan for staff. For more information, go to www.cdc.gov/TCEOnline and search for course number "WB2010."

Molecular Training Materials

2013 APHL Molecular Training Workshop 2013 APHL Molecular Resources Website Webinar 2009 APHL Molecular Testing Webinar

CONTACT

GUISOU PIÑEYRO, MS, MPH

Senior Specialist, Newborn Screening & Genetics 240.485.2736(2) guisou.pineyro@aphl.org

PAST CONFERENCES

2014 Newborn Screening and Genetics Testing Symposium Anaheim, CA

RELATED CONTENT

NewSTEPs Educational Resources

NewSTEPs Quality Practice Resources

What Can You Do?

- Request access to the NBS Molecular Resources
 Website from APHL
- Describe your liquid handling solutions for DNA
 Extraction, PCR Set up or the On-Card Assay Method
- Fill out Molecular Assay Description forms to describe your molecular assays

NBS Molecular Resources Website

To add program members: Guisou Pineyro guisou.pineyro@aphl.org

Scientific questions and suggestions: Laura Hancock Lhancock@cdc.gov

Molecular Assessment Program: Christopher Greene Cgreene@cdc.gov

Molecular Subcommittee Questions: Michele Caggana mxc08@health.state.ny.us

NBS Molecular Subcommittee:

Michele Caggana (NY) – Chairperson

Fred Lorey (CA)

Stan Berberich (IA)

Mark McCann (MN)

Rachel Lee (TX)

Mike Glass (WA)

Mei Baker (WI)

Anne Comeau (MA)

APHL:

Guisou Pineyro Ruhiyyih Degeberg

Jelili Ojodu

Matthias Martin

Melissa Von Hatten

CDC:

Suzanne Cordovado

Christopher Greene

Laura Hancock

Carla Cuthbert

For more information please contact Centers for Disease Control and Prevention

1600 Clifton Road NE, Atlanta, GA 30333
Telephone, 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348
E-mail: cdcinfo@cdc.gov Web: www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

